NEW BRUNSWICK, N.J.,
Oct. 13, 2021 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) will hold a Business
Review for the investment community on Thursday, November 18, 2021, in which company
leaders will share a detailed review of its Pharmaceuticals
business, differentiated strategy and robust pipeline, and
long-term growth outlook.
The Business Review will include:
- Comprehensive Pipeline Overviews for our Six Therapeutic Areas
and Data Sciences available on a virtual platform beginning at
9:00 a.m. ET on November 17, 2021
- Live General Session on November 18,
2021 beginning at 8:30 a.m. ET
and ending at approximately 1:00 p.m.
ET, featuring:
-
- Enterprise remarks from current CEO and Chairman, Alex Gorsky and incoming CEO Joaquin Duato and CFO Joe Wolk
- Insights into Janssen's transformational innovation engine and
commercial capabilities fueling both short and long-term growth
delivered by Jennifer Taubert,
Executive Vice President, Worldwide Chairman and Mathai Mammen, Global Head, Janssen Research
& Development
- Spotlight presentations highlighting key product opportunities
across the Company's current and future pipeline
- Q&A sessions with leaders from the Company's Executive
Committee, and Janssen Research & Development, Commercial, and
Supply Chain organizations
Those planning to attend the event can register at
www.investor.jnj.com starting November
1, 2021. A replay and supporting content will be
posted by the end of the day on November 18, 2021.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS:
This press release contains "forward-looking statements" as defined
in the Private Securities Litigation Reform Act of 1995 regarding,
among other things: future operating and financial performance,
product development, market position and business strategy. The
reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections
of Johnson & Johnson. Risks and uncertainties include, but
are not limited to: risks related to the impact of the COVID-19
global pandemic, such as the scope and duration of the outbreak,
government actions and restrictive measures implemented in
response, material delays and cancellations of medical procedures,
supply chain disruptions and other impacts to the business, or on
the Company's ability to execute business continuity plans, as a
result of the COVID-19 pandemic, economic factors, such as interest
rate and currency exchange rate fluctuations; competition,
including technological advances, new products and patents attained
by competitors; challenges inherent in new product research and
development, including uncertainty of clinical success and
obtaining regulatory approvals; uncertainty of commercial success
for new and existing products; challenges to patents; the impact of
patent expirations; the ability of the Company to successfully
execute strategic plans; the impact of business combinations and
divestitures; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; significant
adverse litigation or government action, including related to
product liability claims; changes to applicable laws and
regulations, including tax laws and global healthcare reforms;
trends toward healthcare cost containment; changes in behavior and
spending patterns of purchasers of healthcare products and
services; financial instability of international economies and
legal systems and sovereign risk; increased scrutiny of the
healthcare industry by government agencies. A further list and
descriptions of these risks, uncertainties and other factors can be
found in Johnson & Johnson's Annual Report on Form
10-K for the fiscal year ended January 3, 2021 including
in the sections captioned "Cautionary Note Regarding
Forward-Looking Statements" and "Item 1A. Risk Factors," in the
Company's most recently filed Quarterly Report on Form 10-Q and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request
from Johnson & Johnson. Any forward-looking statement made
in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information
or future events or developments.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-to-host-business-review-highlighting-pharmaceuticals-301398928.html
SOURCE Johnson & Johnson